Evidence supporting the use of: Resveratrol
For the health condition: Chronic Obstructive Pulmonary Disorder

Links: Go back one page, Tool main page, Ingredients list, Health conditions list, Body systems list

Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Resveratrol, a polyphenolic compound found in grapes and red wine, has been studied for its potential therapeutic effects in Chronic Obstructive Pulmonary Disease (COPD). The scientific interest stems from resveratrol’s anti-inflammatory, antioxidant, and anti-fibrotic properties, which are relevant to the pathogenesis of COPD. Preclinical studies, primarily in animal models and in vitro systems, have demonstrated that resveratrol can inhibit inflammatory cytokine production, reduce oxidative stress, and suppress the activation of pathways such as NF-κB that contribute to lung tissue damage in COPD. Some studies have also shown that resveratrol may improve corticosteroid sensitivity, which is often impaired in COPD patients. However, clinical evidence in humans is limited. A few small-scale pilot studies and early-phase clinical trials have explored resveratrol supplementation in individuals with COPD, showing modest improvements in certain biomarkers of inflammation and oxidative stress, but without robust or consistent improvements in lung function or clinical symptoms. Most systematic reviews and meta-analyses conclude that while the mechanistic rationale is strong and preclinical data are promising, there is insufficient high-quality clinical evidence to recommend resveratrol as a standard adjunctive treatment for COPD at this time. In summary, resveratrol is supported by a scientific rationale and preclinical data for use in COPD, but the evidence from human studies is currently weak, justifying a low to moderate evidence rating.

More about resveratrol
More about Chronic Obstructive Pulmonary Disorder